In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...
Bio-Techne Corp. failed to get shareholder approval on its executive compensation plan. While the vote is nonbinding, a no vote is rare. Only 35% of shareholders supported the plan during the ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high ...
The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Argus Research on November 20, 2025. The analyst firm set a price target for $68.00 expecting TECH to rise to within 12 months (a ...
Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual ...
Bio-Techne Corp. TECH has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference ...
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback